- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Elacetrant is an oral selective estrogen receptor degrading agent (SERD), which is used to treat patients with ER positive, HER2 negative and E...
As a therapeutic drug for ER positive breast cancer, Elacetrant needs to focus on adverse reactions such as dyslipidemia, hepatotoxicity and ...
The common side effects such as nausea, joint pain, and fatigue during Elacestrant treatment can be effectively controlled through a graded man...
Elacetrant is an oral selective estrogen receptor degrading agent (SERD) for the treatment of advanced or metastatic breast cancer patients wit...
The side effects of bimetinib require focused monitoring of cardiac, hepatic, and ocular toxicity, while also paying attention to standardized ...
Binimetinib is a MEK inhibitor primarily used for the treatment of metastatic melanoma and non-small cell lung cancer, and should be used in co...
Bimetinib should focus on the risks of cardiomyopathy, hepatotoxicity, and retinopathy, and regular monitoring of relevant indicators and timel...
Binimetinib is an oral inhibitor targeting MEK1/2 kinase, mainly used to treat melanoma and non-small cell lung cancer carrying BRAFV600E/K mut...
Pacritinib is a novel kinase inhibitor used to treat bone marrow fibrosis with severe thrombocytopenia. Its clinical application should focus o...
Pacritinib is a JAK2/FLT3 inhibitor used to treat bone marrow fibrosis, with a standard dose of 200mg per dose, taken orally twice daily. In te...
